Floatz logo

Panobinostat

Neuroendocrine Tumors

Eli Lilly and CompanySmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
73/ 100

Competitive context

56 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB
Oxodotreotide
Fundación de investigación HM
Phase 3BB
Surufatinib
Shanghai Changzheng Hospital
Phase 3BB
Everolimus
Exelixis
Phase 3BB

View all 50 →

Same molecule, other indications

Panobinostat is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
Non-Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →